Global Nucleic Vaccine Market
Global Nucleic Vaccine Market

Nucleic Vaccine Comprehensive Study by Application (Hospital, Clinic, Others), Disease (AIDS, Hepatitis B and C, Influenza, Warts) Players and Region - Global Market Outlook to 2026

Nucleic Vaccine Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 208 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Nucleic Vaccine?
Genetic cloth from a disease-causing virus or micro organism (a pathogen) is used in nucleic vaccines to elicit an immune response towards it. The genetic cloth in the vaccine should be DNA or RNA, relying on the vaccination; in both instance, it provides guidelines for growing a precise pathogen protein that the immune device will realize as alien (an antigen). When this genetic cloth is injected into host cells, it is study via the cell's very own protein-making equipment and used to make antigens, which then prompt an immune response.

The market study is broken down, by Application (Hospital, Clinic and Others) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from Chinese will contribute to the maximum growth of Global Nucleic Vaccine market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Moderna (United States), CureVac (Germany), Inovio (United States), Sanofi (France), GSK (United Kingdom), CNBG (China), Hualan Bio (China), Zhifei Shengwu (China), Liaoning Chengda (China) and BioKangtai (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are CanSinoBIO (China), Walvax Biotechnology (China) and Fosun Pharma (China).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Nucleic Vaccine market by Type, Application and Region.

On the basis of geography, the market of Nucleic Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease, the sub-segment i.e. AIDS will boost the Nucleic Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, INOVIO a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the signing of a non-binding memorandum of understanding (MOU) with Colombia's Ministry of Health and Social Protection reflecting the intent to advance efforts to combat the pandemic and endemic threat posed by COVID-19 and to better prepare for future public health emergencies. The MOU creates a framework for a collaboration arrangement under which INOVIO and the government plan to explore knowledge sharing, technology licensing, and capacity building that support developing and producing vaccines and other biopharmaceuticals in Colombia. The potential results of these efforts include developing local manufacturing capabilities for INOVIO's DNA medicines and related products and technologies.


Market Trend
  • Growing technological advancements
  • Large number of investing in the R&D sector

Market Drivers
  • Increase in number of ongoing clinical trials

Opportunities
  • Development of new technology of DNA and RNA vaccines are being developed against various diseases like HIV, Zika virus

Restraints
  • Affordability of vaccine price
  • Improper distribution channel

Challenges
  • Small-scale production of vaccine


Key Target Audience
Nucleic Vaccine Manufacturers, Nucleic Vaccine Distributors and Suppliers, Government associations, Market research and consulting firms, Venture capitalists and investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Moderna (United States), CureVac (Germany), Inovio (United States), Sanofi (France), GSK (United Kingdom), CNBG (China), Hualan Bio (China), Zhifei Shengwu (China), Liaoning Chengda (China) and BioKangtai (China) etc.

2. Can we have customized study for Nucleic Vaccine Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Nucleic Vaccine Market by 2026?
Analysts at AMA estimates Nucleic Vaccine Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By Application
  • Hospital
  • Clinic
  • Others
By Disease
  • AIDS
  • Hepatitis B and C
  • Influenza
  • Warts

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in number of ongoing clinical trials
    • 3.3. Market Challenges
      • 3.3.1. Small-scale production of vaccine
    • 3.4. Market Trends
      • 3.4.1. Growing technological advancements
      • 3.4.2. Large number of investing in the R&D sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nucleic Vaccine, by Application, Disease and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Nucleic Vaccine (Value)
      • 5.2.1. Global Nucleic Vaccine by: Application (Value)
        • 5.2.1.1. Hospital
        • 5.2.1.2. Clinic
        • 5.2.1.3. Others
      • 5.2.2. Global Nucleic Vaccine by: Disease (Value)
        • 5.2.2.1. AIDS
        • 5.2.2.2. Hepatitis B and C
        • 5.2.2.3. Influenza
        • 5.2.2.4. Warts
      • 5.2.3. Global Nucleic Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Nucleic Vaccine (Volume)
      • 5.3.1. Global Nucleic Vaccine by: Application (Volume)
        • 5.3.1.1. Hospital
        • 5.3.1.2. Clinic
        • 5.3.1.3. Others
      • 5.3.2. Global Nucleic Vaccine by: Disease (Volume)
        • 5.3.2.1. AIDS
        • 5.3.2.2. Hepatitis B and C
        • 5.3.2.3. Influenza
        • 5.3.2.4. Warts
      • 5.3.3. Global Nucleic Vaccine Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Nucleic Vaccine (Price)
  • 6. Nucleic Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Moderna (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CureVac (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Inovio (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GSK (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CNBG (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hualan Bio (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Zhifei Shengwu (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Liaoning Chengda (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioKangtai (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nucleic Vaccine Sale, by Application, Disease and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Nucleic Vaccine (Value)
      • 7.2.1. Global Nucleic Vaccine by: Application (Value)
        • 7.2.1.1. Hospital
        • 7.2.1.2. Clinic
        • 7.2.1.3. Others
      • 7.2.2. Global Nucleic Vaccine by: Disease (Value)
        • 7.2.2.1. AIDS
        • 7.2.2.2. Hepatitis B and C
        • 7.2.2.3. Influenza
        • 7.2.2.4. Warts
      • 7.2.3. Global Nucleic Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Nucleic Vaccine (Volume)
      • 7.3.1. Global Nucleic Vaccine by: Application (Volume)
        • 7.3.1.1. Hospital
        • 7.3.1.2. Clinic
        • 7.3.1.3. Others
      • 7.3.2. Global Nucleic Vaccine by: Disease (Volume)
        • 7.3.2.1. AIDS
        • 7.3.2.2. Hepatitis B and C
        • 7.3.2.3. Influenza
        • 7.3.2.4. Warts
      • 7.3.3. Global Nucleic Vaccine Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Nucleic Vaccine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nucleic Vaccine: by Application(USD Million)
  • Table 2. Nucleic Vaccine Hospital , by Region USD Million (2015-2020)
  • Table 3. Nucleic Vaccine Clinic , by Region USD Million (2015-2020)
  • Table 4. Nucleic Vaccine Others , by Region USD Million (2015-2020)
  • Table 5. Nucleic Vaccine: by Disease(USD Million)
  • Table 6. Nucleic Vaccine AIDS , by Region USD Million (2015-2020)
  • Table 7. Nucleic Vaccine Hepatitis B and C , by Region USD Million (2015-2020)
  • Table 8. Nucleic Vaccine Influenza , by Region USD Million (2015-2020)
  • Table 9. Nucleic Vaccine Warts , by Region USD Million (2015-2020)
  • Table 10. South America Nucleic Vaccine, by Country USD Million (2015-2020)
  • Table 11. South America Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 12. South America Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 13. Brazil Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 14. Brazil Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 15. Argentina Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 16. Argentina Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 17. Rest of South America Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 18. Rest of South America Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 19. Asia Pacific Nucleic Vaccine, by Country USD Million (2015-2020)
  • Table 20. Asia Pacific Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 21. Asia Pacific Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 22. China Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 23. China Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 24. Japan Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 25. Japan Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 26. India Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 27. India Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 28. South Korea Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 29. South Korea Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 30. Taiwan Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 31. Taiwan Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 32. Australia Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 33. Australia Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 36. Europe Nucleic Vaccine, by Country USD Million (2015-2020)
  • Table 37. Europe Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 38. Europe Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 39. Germany Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 40. Germany Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 41. France Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 42. France Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 43. Italy Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 44. Italy Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 45. United Kingdom Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 46. United Kingdom Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 47. Netherlands Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 48. Netherlands Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 49. Rest of Europe Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 50. Rest of Europe Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 51. MEA Nucleic Vaccine, by Country USD Million (2015-2020)
  • Table 52. MEA Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 53. MEA Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 54. Middle East Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 55. Middle East Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 56. Africa Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 57. Africa Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 58. North America Nucleic Vaccine, by Country USD Million (2015-2020)
  • Table 59. North America Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 60. North America Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 61. United States Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 62. United States Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 63. Canada Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 64. Canada Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 65. Mexico Nucleic Vaccine, by Application USD Million (2015-2020)
  • Table 66. Mexico Nucleic Vaccine, by Disease USD Million (2015-2020)
  • Table 67. Nucleic Vaccine Sales: by Application(K Units)
  • Table 68. Nucleic Vaccine Sales Hospital , by Region K Units (2015-2020)
  • Table 69. Nucleic Vaccine Sales Clinic , by Region K Units (2015-2020)
  • Table 70. Nucleic Vaccine Sales Others , by Region K Units (2015-2020)
  • Table 71. Nucleic Vaccine Sales: by Disease(K Units)
  • Table 72. Nucleic Vaccine Sales AIDS , by Region K Units (2015-2020)
  • Table 73. Nucleic Vaccine Sales Hepatitis B and C , by Region K Units (2015-2020)
  • Table 74. Nucleic Vaccine Sales Influenza , by Region K Units (2015-2020)
  • Table 75. Nucleic Vaccine Sales Warts , by Region K Units (2015-2020)
  • Table 76. South America Nucleic Vaccine Sales, by Country K Units (2015-2020)
  • Table 77. South America Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 78. South America Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 79. Brazil Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 80. Brazil Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 81. Argentina Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 82. Argentina Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 83. Rest of South America Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 84. Rest of South America Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 85. Asia Pacific Nucleic Vaccine Sales, by Country K Units (2015-2020)
  • Table 86. Asia Pacific Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 87. Asia Pacific Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 88. China Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 89. China Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 90. Japan Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 91. Japan Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 92. India Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 93. India Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 94. South Korea Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 95. South Korea Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 96. Taiwan Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 97. Taiwan Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 98. Australia Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 99. Australia Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 100. Rest of Asia-Pacific Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 101. Rest of Asia-Pacific Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 102. Europe Nucleic Vaccine Sales, by Country K Units (2015-2020)
  • Table 103. Europe Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 104. Europe Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 105. Germany Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 106. Germany Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 107. France Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 108. France Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 109. Italy Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 110. Italy Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 111. United Kingdom Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 112. United Kingdom Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 113. Netherlands Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 114. Netherlands Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 115. Rest of Europe Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 116. Rest of Europe Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 117. MEA Nucleic Vaccine Sales, by Country K Units (2015-2020)
  • Table 118. MEA Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 119. MEA Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 120. Middle East Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 121. Middle East Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 122. Africa Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 123. Africa Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 124. North America Nucleic Vaccine Sales, by Country K Units (2015-2020)
  • Table 125. North America Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 126. North America Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 127. United States Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 128. United States Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 129. Canada Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 130. Canada Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 131. Mexico Nucleic Vaccine Sales, by Application K Units (2015-2020)
  • Table 132. Mexico Nucleic Vaccine Sales, by Disease K Units (2015-2020)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Nucleic Vaccine: by Application(USD Million)
  • Table 144. Nucleic Vaccine Hospital , by Region USD Million (2021-2026)
  • Table 145. Nucleic Vaccine Clinic , by Region USD Million (2021-2026)
  • Table 146. Nucleic Vaccine Others , by Region USD Million (2021-2026)
  • Table 147. Nucleic Vaccine: by Disease(USD Million)
  • Table 148. Nucleic Vaccine AIDS , by Region USD Million (2021-2026)
  • Table 149. Nucleic Vaccine Hepatitis B and C , by Region USD Million (2021-2026)
  • Table 150. Nucleic Vaccine Influenza , by Region USD Million (2021-2026)
  • Table 151. Nucleic Vaccine Warts , by Region USD Million (2021-2026)
  • Table 152. South America Nucleic Vaccine, by Country USD Million (2021-2026)
  • Table 153. South America Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 154. South America Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 155. Brazil Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 156. Brazil Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 157. Argentina Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 158. Argentina Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 159. Rest of South America Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 160. Rest of South America Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 161. Asia Pacific Nucleic Vaccine, by Country USD Million (2021-2026)
  • Table 162. Asia Pacific Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 163. Asia Pacific Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 164. China Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 165. China Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 166. Japan Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 167. Japan Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 168. India Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 169. India Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 170. South Korea Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 171. South Korea Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 172. Taiwan Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 173. Taiwan Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 174. Australia Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 175. Australia Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 176. Rest of Asia-Pacific Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 177. Rest of Asia-Pacific Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 178. Europe Nucleic Vaccine, by Country USD Million (2021-2026)
  • Table 179. Europe Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 180. Europe Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 181. Germany Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 182. Germany Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 183. France Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 184. France Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 185. Italy Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 186. Italy Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 187. United Kingdom Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 188. United Kingdom Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 189. Netherlands Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 190. Netherlands Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 191. Rest of Europe Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 192. Rest of Europe Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 193. MEA Nucleic Vaccine, by Country USD Million (2021-2026)
  • Table 194. MEA Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 195. MEA Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 196. Middle East Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 197. Middle East Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 198. Africa Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 199. Africa Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 200. North America Nucleic Vaccine, by Country USD Million (2021-2026)
  • Table 201. North America Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 202. North America Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 203. United States Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 204. United States Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 205. Canada Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 206. Canada Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 207. Mexico Nucleic Vaccine, by Application USD Million (2021-2026)
  • Table 208. Mexico Nucleic Vaccine, by Disease USD Million (2021-2026)
  • Table 209. Nucleic Vaccine Sales: by Application(K Units)
  • Table 210. Nucleic Vaccine Sales Hospital , by Region K Units (2021-2026)
  • Table 211. Nucleic Vaccine Sales Clinic , by Region K Units (2021-2026)
  • Table 212. Nucleic Vaccine Sales Others , by Region K Units (2021-2026)
  • Table 213. Nucleic Vaccine Sales: by Disease(K Units)
  • Table 214. Nucleic Vaccine Sales AIDS , by Region K Units (2021-2026)
  • Table 215. Nucleic Vaccine Sales Hepatitis B and C , by Region K Units (2021-2026)
  • Table 216. Nucleic Vaccine Sales Influenza , by Region K Units (2021-2026)
  • Table 217. Nucleic Vaccine Sales Warts , by Region K Units (2021-2026)
  • Table 218. South America Nucleic Vaccine Sales, by Country K Units (2021-2026)
  • Table 219. South America Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 220. South America Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 221. Brazil Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 222. Brazil Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 223. Argentina Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 224. Argentina Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 225. Rest of South America Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 226. Rest of South America Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 227. Asia Pacific Nucleic Vaccine Sales, by Country K Units (2021-2026)
  • Table 228. Asia Pacific Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 229. Asia Pacific Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 230. China Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 231. China Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 232. Japan Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 233. Japan Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 234. India Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 235. India Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 236. South Korea Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 237. South Korea Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 238. Taiwan Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 239. Taiwan Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 240. Australia Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 241. Australia Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 242. Rest of Asia-Pacific Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 243. Rest of Asia-Pacific Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 244. Europe Nucleic Vaccine Sales, by Country K Units (2021-2026)
  • Table 245. Europe Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 246. Europe Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 247. Germany Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 248. Germany Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 249. France Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 250. France Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 251. Italy Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 252. Italy Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 253. United Kingdom Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 254. United Kingdom Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 255. Netherlands Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 256. Netherlands Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 257. Rest of Europe Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 258. Rest of Europe Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 259. MEA Nucleic Vaccine Sales, by Country K Units (2021-2026)
  • Table 260. MEA Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 261. MEA Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 262. Middle East Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 263. Middle East Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 264. Africa Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 265. Africa Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 266. North America Nucleic Vaccine Sales, by Country K Units (2021-2026)
  • Table 267. North America Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 268. North America Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 269. United States Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 270. United States Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 271. Canada Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 272. Canada Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 273. Mexico Nucleic Vaccine Sales, by Application K Units (2021-2026)
  • Table 274. Mexico Nucleic Vaccine Sales, by Disease K Units (2021-2026)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nucleic Vaccine: by Application USD Million (2015-2020)
  • Figure 5. Global Nucleic Vaccine: by Disease USD Million (2015-2020)
  • Figure 6. South America Nucleic Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Nucleic Vaccine Share (%), by Country
  • Figure 8. Europe Nucleic Vaccine Share (%), by Country
  • Figure 9. MEA Nucleic Vaccine Share (%), by Country
  • Figure 10. North America Nucleic Vaccine Share (%), by Country
  • Figure 11. Global Nucleic Vaccine: by Application K Units (2015-2020)
  • Figure 12. Global Nucleic Vaccine: by Disease K Units (2015-2020)
  • Figure 13. South America Nucleic Vaccine Share (%), by Country
  • Figure 14. Asia Pacific Nucleic Vaccine Share (%), by Country
  • Figure 15. Europe Nucleic Vaccine Share (%), by Country
  • Figure 16. MEA Nucleic Vaccine Share (%), by Country
  • Figure 17. North America Nucleic Vaccine Share (%), by Country
  • Figure 18. Global Nucleic Vaccine share by Players 2020 (%)
  • Figure 19. Global Nucleic Vaccine share by Players (Top 3) 2020(%)
  • Figure 20. Global Nucleic Vaccine share by Players (Top 5) 2020(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Moderna (United States) Revenue, Net Income and Gross profit
  • Figure 23. Moderna (United States) Revenue: by Geography 2020
  • Figure 24. CureVac (Germany) Revenue, Net Income and Gross profit
  • Figure 25. CureVac (Germany) Revenue: by Geography 2020
  • Figure 26. Inovio (United States) Revenue, Net Income and Gross profit
  • Figure 27. Inovio (United States) Revenue: by Geography 2020
  • Figure 28. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi (France) Revenue: by Geography 2020
  • Figure 30. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 32. CNBG (China) Revenue, Net Income and Gross profit
  • Figure 33. CNBG (China) Revenue: by Geography 2020
  • Figure 34. Hualan Bio (China) Revenue, Net Income and Gross profit
  • Figure 35. Hualan Bio (China) Revenue: by Geography 2020
  • Figure 36. Zhifei Shengwu (China) Revenue, Net Income and Gross profit
  • Figure 37. Zhifei Shengwu (China) Revenue: by Geography 2020
  • Figure 38. Liaoning Chengda (China) Revenue, Net Income and Gross profit
  • Figure 39. Liaoning Chengda (China) Revenue: by Geography 2020
  • Figure 40. BioKangtai (China) Revenue, Net Income and Gross profit
  • Figure 41. BioKangtai (China) Revenue: by Geography 2020
  • Figure 42. Global Nucleic Vaccine: by Application USD Million (2021-2026)
  • Figure 43. Global Nucleic Vaccine: by Disease USD Million (2021-2026)
  • Figure 44. South America Nucleic Vaccine Share (%), by Country
  • Figure 45. Asia Pacific Nucleic Vaccine Share (%), by Country
  • Figure 46. Europe Nucleic Vaccine Share (%), by Country
  • Figure 47. MEA Nucleic Vaccine Share (%), by Country
  • Figure 48. North America Nucleic Vaccine Share (%), by Country
  • Figure 49. Global Nucleic Vaccine: by Application K Units (2021-2026)
  • Figure 50. Global Nucleic Vaccine: by Disease K Units (2021-2026)
  • Figure 51. South America Nucleic Vaccine Share (%), by Country
  • Figure 52. Asia Pacific Nucleic Vaccine Share (%), by Country
  • Figure 53. Europe Nucleic Vaccine Share (%), by Country
  • Figure 54. MEA Nucleic Vaccine Share (%), by Country
  • Figure 55. North America Nucleic Vaccine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Moderna (United States)
  • CureVac (Germany)
  • Inovio (United States)
  • Sanofi (France)
  • GSK (United Kingdom)
  • CNBG (China)
  • Hualan Bio (China)
  • Zhifei Shengwu (China)
  • Liaoning Chengda (China)
  • BioKangtai (China)
Additional players considered in the study are as follows:
CanSinoBIO (China) , Walvax Biotechnology (China) , Fosun Pharma (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation